Patent application number | Description | Published |
20080262013 | OXYMORPHONE CONTROLLED RELEASE FORMULATIONS - The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief. | 10-23-2008 |
20090030026 | Sustained release formulations of nalbuphine - Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided. | 01-29-2009 |
20090169587 | Chronotherapeutic dosage forms - A chronotherapeutic pharmaceutical formulation comprising a core containing an active agent (e.g., a drug) and a surfactant and a delayed release compression coating comprising a natural or synthetic gum applied onto the surface of the core. | 07-02-2009 |
20090192183 | Oxymorphone Controlled Release Formulations - The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief. | 07-30-2009 |
20110217336 | CHRONOTHERAPEUTIC DOSAGE FORMS AND METHODS OF TREATMENT USING CHRONOTHERAPY - A chronotherapeutic pharmaceutical formulation comprising a core containing an active agent (e.g., a drug) and a delayed release compression coating comprising a natural or synthetic gum applied onto the surface of the core. | 09-08-2011 |
20130164350 | SUSTAINED RELEASE FORMULATION OF NALBUPHINE - Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided. | 06-27-2013 |
20140134250 | OXYMORPHONE CONTROLLED RELEASE FORMULATIONS - The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief. | 05-15-2014 |
20140242166 | SUSTAINED RELEASE MATRIX SYSTEMS FOR HIGHLY SOLUBLE DRUGS - Disclosed are sustained release oral solid dosage forms comprising a therapeutically effective amount of a medicament having a solubility of more than about 10 g/l; a pH modifying agent; and a sustained release matrix comprising a gelling agent, said gelling agent comprising a heteropolysaccharide gum and a homopolysaccharide gum capable of cross-linking said heteropolysaccharide gum when exposed to an environmental fluid, said dosage form providing a sustained release of said medicament after oral administration to human patients. | 08-28-2014 |
20140271852 | SUSTAINED RELEASE FORMULATION OF NALBUPHINE - Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided. | 09-18-2014 |
20140315937 | SUSTAINED RELEASE FORMULATION OF NALBUPHINE - Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided. | 10-23-2014 |